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Real-world evidence on the effectiveness 
and safety of gliclazide extended-release 
treatment in Indian patients with type 2  
diabetes undergoing Ramadan fast:  
an analysis from the global  
DIA-RAMADAN study
Abstract
Backgroud. Glycaemic imbalance, especially hypogly-
caemia, is one of the greatest risks for patients with 
type 2 diabetes mellitus (T2DM) during Ramadan 
fasting. This paper outlines the efficacy and safety 
of gliclazide extended-release (XR) in Indian patients 
with T2DM enrolled in the global DIA-RAMADAN study.
Methods. Adults (aged ≥ 18 years) with T2DM who 
chose to fast during Ramadan and received a gliclazide-
based regimen once daily for 90 days before Ramadan 
were included in the study. Baseline and end-of-study 
visits were conducted 6–8 weeks before and 4–6 weeks 
after Ramadan, respectively. The primary outcome 
was the incidence of ≥ 1 symptomatic hypoglycaemic 
event (HE). Changes in glycated haemoglobin (HbA1c), 
fasting plasma glucose (FPG), and body weight were 
secondary outcomes.
Results. Among 246 Indian patients enrolled in the 
study, most (78.9%, n = 194) were at moderate/low 
risk as per the International Diabetes Federation and 
Diabetes and Ramadan guidelines. Most patients 
(69.1%) received gliclazide XR as monotherapy, and 
the rest received gliclazide XR with metformin or other 
antidiabetic therapy. Significant reductions in HbA1c 
(−0.5 ± 0.8%, P < 0.001) and FPG (−21.8 ± 59.4 mg/dL, 
P < 0.001) levels were observed but the slight reduc-
tion in body weight was not statistically significant 
(−0.3 ± 3.7 kg, P = 0.614) in patients post-Ramadan. 
Overall, no HE was reported in Indian patients with 
T2DM during Ramadan fasting.
Conclusion. Overall, the effectiveness and safety of 
gliclazide XR in Indian patients were consistent with 
that observed in the global cohort. Gliclazide XR sig-
nificantly reduced HbA1c with no incidence of hypogly-
caemic events in Indian patients with type 2 diabetes 
undergoing Ramadan fast, suggesting that gliclazide 
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XR may be used without dose modification at Iftar to 
maintain optimal glycaemic control during Ramadan. 
(Clin Diabetol 2021; 10; 2: 215–222)
Key words: gliclazide, glycated haemoglobin, 
hypoglycaemia, Ramadan, type 2 diabetes mellitus
Introduction
Diabetes mellitus is one of the most common 
diseases globally with a rapidly increasing prevalence 
with an estimated 51% rise by 2045 resulting in almost 
700 million people living with diabetes [1]. India is 
projected to be the diabetes capital of the world with 
approximately 134 million people with diabetes by this 
date [1, 2]. Type 2 diabetes mellitus (T2DM) accounts 
for around 90% of all diabetes cases [1]. 
Fasting and feasting are integral parts of many 
religions and cultures in India [2]. Ramadan is one of 
the five pillars of Islam, and fasting during Ramadan is 
observed by over 1 billion Muslims worldwide [2–4]. A 
multicentre epidemiology survey of diabetes and Rama-
dan (EPIDAR) in 12,243 Muslims worldwide, including 
India, revealed that 78.7% of patients with T2DM fast 
for at least 15 days during Ramadan [4]. The CREED (a 
multi-country retrospective observational study of the 
management and outcomes of patients with diabetes 
during Ramadan) study of 13 countries reported that 
94.2% of patients with T2DM fast for at least 15 days, 
and 63.6% fast every day during the holy month of 
Ramadan [5, 6]. Within the Muslim community, there is 
an intense desire to participate in fasting, even among 
those who are eligible for an exemption due to medical 
conditions [2, 3, 5] People observe the fast (without 
food or water) during daylight that can last up to 20 
hours depending on their location in the world [3]. 
The onset of Ramadan causes a sudden shift in meal-
times, sleep patterns, physical activity, and meal sizes 
[2–4]. One of the major complications associated with 
diabetic fasting is hypoglycaemia [2–5]. The EPIDAR 
study showed that incidence of severe hyperglycaemia 
increased 5-fold and the risk of hospitalization due 
to hypoglycaemia increased 7.5-fold in patients with 
T2DM during Ramadan fasting [4, 7]. Therefore, gly-
caemic control during fasting is a challenge as patients 
with T2DM refrain from food, drink, and medications 
between dawn and dusk. Both fasting and antihy-
perglycemic therapy could increase the risk of severe 
hypoglycaemia in patients with T2DM.
The International Diabetes Federation (IDF), and 
Diabetes and Ramadan (DAR) guidelines have provided 
the necessary guidance for managing T2DM during 
Ramadan [3]. Treatments that stabilize blood glucose 
levels with the lowest risk of hypoglycaemia during 
fasting are highly recommended [2, 3]. Sulfonylureas 
(SUs) are recommended for treating T2DM owing to 
their wide clinical experience and lower therapy costs 
[8]. They are also widely used to control blood glucose 
in patients with T2DM in India [2, 9–12] Although 
concerns have been raised regarding the use of SUs 
during Ramadan due to increased risk (~13–20%) of 
hypoglycaemia [3], this risk is lower during fasting with 
newer generation SUs like gliclazide extended-release 
(XR) [8, 13–15]. 
Indians have distinct dietary habits and consume 
diets predominantly consisting of carbohydrates pro-
viding up to 64.1% of total energy thus, predisposing 
Indian Muslims to a higher risk of hypoglycaemia during 
Ramadan [2, 16]. Additionally, the safety and efficacy 
of gliclazide XR treatment in Indian patients with T2DM 
during Ramadan have not yet been demonstrated in 
a real-world setting. Recently, the DIA-RAMADAN study 
was conducted in nine countries, including India, and 
reported the efficacy and safety of gliclazide XR in pa-
tients with T2DM during Ramadan fasting [17]. Herein 
is presented the efficacy and safety data of gliclazide 
XR in the Indian subgroup of patients who participated 
in the DIA-RAMADAN study.
Material and methods
Ethics
This study was carried out in accordance with the 
Declaration of Helsinki and the International Confer-
ence on Harmonization Good Clinical Practice guide-
lines. Approval was obtained from local institutional 
review boards, ethics committees, and regulatory au-
thorities. Written informed consent was obtained from 
all patients before the commencement of the study. The 
trial was registered at ClinicalTrials.gov (NCT04132934).
Study design
Hassanein et al. [17] have recently published the 
detailed methodology of the DIA-RAMADAN study. In 
brief, DIA-RAMADAN was an international, real-world, 
prospective, observational study conducted during the 
holy month of Ramadan in 2019 at 64 clinical centres 
from nine Asian and Middle-Eastern countries including 
India. Owing to its observational nature, T2DM was 
managed per the local standard clinical practice. Patient 
visits were scheduled as per recommendations of the 
IDF-DAR guidelines, i.e., one visit pre- and another visit 
post-Ramadan. 
Patient population
Data from Indian patients (aged ≥ 18 years) with 
T2DM (controlled or sub-optimally controlled) defined 
according to American Diabetes Association guidelines 
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were included. Patients with fasting plasma glucose 
(FPG) levels ≥ 126 mg/dL, 2-hour blood glucose level 
≥ 200 mg/dL in an oral glucose tolerance test, or with 
glycated haemoglobin (HbA1c) level ≥ 6.5%, body mass 
index (BMI) ≥ 25–≤ 45 kg/m2 and treated with gliclazide 
XR (monotherapy or in combination with antidiabetic 
therapy except for insulin) at least 90 days before their 
pre-Ramadan visit, were included in the study. Patients 
were included if they were familiar with self-monitoring 
of blood glucose levels and intended to fast during 
Ramadan. Patients were excluded if they needed insulin 
therapy, had a severe liver or renal failure, HbA1c level 
≥ 9%, were contraindicated for gliclazide XR treatment 
according to the summary of product characteristics, 
or were on miconazole treatment. Pregnant or breast-
feeding women or patients with a former history of 
severe or repeated hypoglycaemic events (HEs) without 
a triggering factor within the year before study initia-
tion were excluded. Only data from Indian patients 
were included.
Study procedure
There were two visits in the study: the first pre-
Ramadan visit was planned 6–8 weeks before Rama-
dan when the patient eligibility was assessed, and 
baseline information was collected. The second visit 
was planned 4–6 weeks after Ramadan. In addition, 
Ramadan-focused education was provided to patients 
per IDF-DAR guidelines at the first visit. They were 
also provided with a diary to record any changes in 
the treatment regimen, details of any symptoms indi-
cating hypoglycaemia, or other adverse events (AEs) 
throughout the study.
Study treatment
Management of T2DM in patients was in accord-
ance with standard clinical practice at each participat-
ing centre. Gliclazide XR 60 mg tablets were orally 
administered once daily at breakfast before Ramadan, 
and patients were advised to adjust the timing for Iftar 
(post-sunset meal) during the Ramadan period, based 
on recommendations of the current IDF-DAR guideline 
[3] at the physician’s discretion. Post-Ramadan, gli-
clazide XR was continued per the pre-Ramadan timings. 
The global study was conducted with a gliclazide MR 
formulation that allows progressive drug release in a 
once-daily dose regimen, which is available as Gliclazide 
XR in India.
Data collection and endpoints
Data concerning patients’ age, gender, height, 
body weight, blood pressure, heart rate, HbA1c, FPG, 
history of alcohol and tobacco consumption, occupa-
tion, physical activity, IDF-DAR risk classification, T2DM 
disease and treatment history, relevant medical/surgi-
cal history, concomitant treatments, nutritional habits 
outside Ramadan, and fasting during previous and cur-
rent Ramadan were recorded. Adherence to gliclazide 
XR treatment, concomitant medications, and data on 
safety (AEs and HEs) were also documented. All the 
data, including records of the patient’s paper diary, 
were collected by investigators using an electronic case 
report form and kept confidential. 
The primary endpoint of the study was the pro-
portion of patients with more than one symptomatic 
HE (either suggestive or confirmed by a measured 
glucose concentration of ≤ 3.9 mmol/L or ≤ 70 mg/
dL). Changes in HbA1c and FPG levels, change in body 
weight between pre-Ramadan baseline visit and post-
Ramadan visit, and proportion of patients with at least 
one confirmed HE (asymptomatic or symptomatic) 
during Ramadan were the secondary endpoints. The 
proportion of patients with at least one severe or any 
other type of HE was also considered. Study-specific 
definitions of HEs are described in Table 1. Other AEs 
were also recorded during the study. 
Statistical analysis
Continuous and quantitative variables were sum-
marized using descriptive statistics and compared using 
paired t-test or Wilcoxon signed-rank test as applicable 
at type I error (alpha) of 5%. Categorical data were 
presented as frequency count (n) and percentage (%) 
and were compared using the c2 test or Fisher’s exact 
test. Analyses were performed using SAS® software, 
version 9.4 (SAS Institute, North Carolina, USA).
Results
Patients’ baseline characteristics  
and IDF-DAR risk categorization
A total of 1214 patients from nine countries were 
included. Of these, 640 (52.7%) were from the Asia 
Pacific region with 255 from India. However, 9 out of 
255 patients were excluded as they met one or more 
exclusion criteria, were noncompliant to inclusion 
criteria, or withdrew informed consent. A total of 
237 (96.3%) patients completed the study, whereas 9 
(3.7%) did not due to nonmedical reasons. Patients and 
physicians were given the option for an unscheduled 
visit depending on the patient’s need or physician’s 
preference; 4 (1.6%) patients had unscheduled visits of 
which 3 were ‘regular visits’ and 1 for a reason other 
than AE or HE.
Patient characteristics at pre-Ramadan visit are 
summarized in Table 2. Among 246 patients analysed, 
112 (45.5%) were women. The mean age of patients 
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Table 1. Definition of hypoglycaemic events
Types of HE Definition Typical hypoglycaemia symptoms
Asymptomatic HE Absence of typical hypoglycaemia symptoms with 
measured glucose concentration < 70 mg/dL
Sweating, pallor, tremor, intense hunger, pound-
ing heart, visual disturbance, drowsiness, weak-
ness, dizziness, difficulty in concentrating, dif-
ficulty in speaking or writing, incoordination, un-
explained behaviour or mood change, confusion, 
nausea, or headache
Confirmed symptomatic HE Presence of typical symptoms of hypoglycaemia 
with glucose concentration ≤ 72 mg/dL
Suggestive HE Presence of typical hypoglycaemic symptoms 
without a measured glucose concentration or with 
measured glucose concentration > 72 mg/dL
Severe hypoglycaemia Symptoms of severe cognitive impairment and re-
quiring third-party assistance for recovery with  
a measured glucose concentration < 70 mg/dL
–
HE: hypoglycaemic event
Table 2 Patient characteristics before Ramadan
Characteristics n = 246
Age, years 53.0 ± 10.6
Gender, female 112 (45.5)
Height, cm 162.6 ± 8.9
Weight, kg 73.4 ± 10.9
Body mass index, kg/m2 27.8 ± 3.9
Heart rate, bpm 84.9 ± 9.2
Systolic blood pressure, mm Hg 128.8 ± 14.2
Diastolic blood pressure, mm Hg 80.6 ± 8.5
Working status
Active full-time worker 110 (44.7)
Active part-time worker 22 (8.9)
Non-active worker 40 (16.3)
Student 1 (0.4)
Retired 15 (6.1)






Duration of T2DM, years 5.8 ± 6.6
HbA1c, % 7.3 ± 0.8
FPG, mg/dL 142.7 ± 53.0
Dose of gliclazide XR, mg 70.2 ± 24.6
Dose of metformin, mg 1023.9 ± 436.3
IDF-DAR risk categories
Category 1: Very high risk 0 (0.0)
Category 2: High risk 52 (21.1)
Category 3: Moderate/low risk 194 (78.9)
Medical history*
Established cardiovascular disease 1 (0.4)
Arterial hypertension 57 (23.2)
Dyslipidaemia 46 (18.7)
Cardiovascular therapies*
Statin or ezetimibe 53 (21.5)
ACEi or ARB 35 (14.2)
Beta-blocker 5 (2.0)
Antiplatelet agents 5 (2.0)
Calcium channel blockers 11 (4.5)
Diuretics 10 (4.1)
Nutritional habits outside Ramadan 
Number of meals consumed per day 2.6±0.6
Number of snacks consumed per day 1.4±0.9
Fasting during previous Ramadan
Fasting during previous Ramadan 243 (98.8)
During the whole previous Ramadan 230 (93.5)
Not during the whole previous Ramadan 13 (5.3)
If not, reason: nonmedical reason 13 (5.3)
Type of antidiabetic treatments at baseline
Gliclazide XR alone 170 (69.1)
Gliclazide XR + metformin 54 (22.0)
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was 53 ± 10.6 years; duration of T2DM, 5.8 ± 6.6 
years; and BMI, 27.8 ± 3.9 kg/m2. Baseline HbA1c and 
FPG levels were 7.3 ± 0.8% and 142.7 ± 53.0 mg/
dL, respectively. Risk categorization of patients as per 
IDF-DAR guidelines showed that most (78.9%) patients 
had moderate/low risk and 21.1% were at high risk. No 
Indian patients belonged to the very high-risk category. 
However, 105 (42.7%) patients were advised not to 
fast during Ramadan by physicians. Of 243 (98.8%) 
patients who had undergone fasting during previous 
Ramadan, 230 (93.5%) fasted for the whole month of 
previous Ramadan and 13 (5.3%) broke their fast early 
in the month due to non-medical reasons in previous 
Ramadan. The average number of meals and snacks 
consumed by patients outside Ramadan was 2.6 ± 0.6 
and 1.4 ± 0.9 per day, respectively. A large proportion 
of patients (69.1%) were on monotherapy at baseline. 
The mean daily dose of gliclazide XR 60 mg was 70.2 
± 24.6 mg and no dose modification was done dur-
ing the study. 
Nutritional habits and fasting during Ramadan
Approximately 134 (54.5%) patients changed 
their meal type, and 103 (41.9%) changed their meal 
size [either larger (26%) or smaller (15.9%)] during 
Ramadan compared to pre-Ramadan (Table 3). Patients 
consumed more carbohydrates (26.8%), fats (43.9%) 
and proteins (31.3%) during their Ramadan meals. 
However, the average number of meals and snacks 
consumed by patients was reduced to 2.2 ± 0.4 and 0.8 
± 0.7 per day during Ramadan, respectively. On aver-
age, Indian patients fasted for 29.1 ± 1.7 days, 13.9 ± 
1.9 hours per day during Ramadan (Table 3). A total of 
183 (74.4%) patients broke their fast during Ramadan, 
and 6 (2.4%) broke the fast for three consecutive days 
due to nonmedical (n = 1) or other (n = 5) reasons. 
Exposure and adherence to gliclazide  
XR treatment
Gliclazide XR treatment was observed for a mean 
duration of 63.1 ± 20.2, 29.0 ± 0.2, and 30.8 ± 10.4 
days before, during, and after Ramadan, respectively 
(Table 4). During Ramadan, 172 (69.9%) patients re-
ceived 60 mg of gliclazide XR once daily, 40 (16.3%) 
received 120 mg, 19 (7.7%) received 90 mg, and 15 
(6.1%) received 30 mg. A total of 240 (97.6%) patients 
received gliclazide XR as per the prescription, and 4 
(1.6%) patients skipped their medication for around 1.8 
± 0.5 intakes due to nonmedical reasons (n = 3) or AEs 
other than hypoglycaemia (n = 1). Higher adherence 
(99.9 ± 0.8%) to gliclazide XR was reported during 
Ramadan, no changes were made in the mean dose 
Gliclazide XR + SGLT2i with or without 
metformin
2 (0.8)
Gliclazide XR + DPP4i with or without 
metformin
17 (6.9)
Gliclazide XR + TZD with or without  
metformin
2 (0.8)
Gliclazide XR + SGLT2i + other 1 (0.4)
Gliclazide XR + Other 1 (0.4)
Number of antidiabetic drugs at baseline
One 170 (69.1)
Two 59 (24.0)
≥ Three 17 (6.9)
Duration of treatment, months
Gliclazide alone 17.1±49.5
Gliclazide + metformin 43.5±75.7
Gliclazide + DPP4i 6.7±3.6
Data are presented as mean ± SD or n (%). *Number of patients with at 
least one relevant medical history/concomitant treatment. ACEi: angio-
tensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; 
DPP4i: dipeptidyl peptidase 4 inhibitor; FPG: fasting plasma glucose; 
HbA1c: glycated haemoglobin; SGLT2i: sodium-glucose cotransporter 
2 inhibitor; T2DM: type 2 diabetes mellitus; TZD: thiazolidinedione; XR: 
extended-release
Table 3: Nutritional habit, meals, and fasting during 
Ramadan
Parameters Patients,  
n = 246
Nutritional habits during Ramadan
The average number of meals consumed  
per day 
2.2 ± 0.4
The average number of snacks consumed  
per day 
0.8 ± 0.7
Change of size of a meal during Ramadan 103 (41.9)
Meals larger during Ramadan period 64 (26.0)
Meals smaller during the Ramadan period 39 (15.9)
Change of type of meal during Ramadan 134 (54.5)
More carbohydrate in a meal 66 (26.8%)
More protein in a meal 77 (31.3%)
More fat in a meal 108 (43.9%)
Fasting during Ramadan
Number of days fasted during Ramadan 29.1 ± 1.7 
Number of hours/day fasted during Ramadan 13.9 ± 1.9
Patients who broke the fast during Ramadan 183 (74.4) 
Patients who broke the fast for more than  
3 consecutive days
6 (2.4)
Data are presented as mean ± SD or n (%)
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of gliclazide XR, and none discontinued the treatment 
during Ramadan.
Hypoglycaemic events
No HEs were reported during the study following 
treatment with gliclazide XR in Indian patients. 
Change in HbA1c, FPG, and body weight 
Changes in HbA1c and FPG levels and body weight 
were calculated from pre-Ramadan to post-Ramadan 
visits. Mean HbA1c reduced from baseline (7.3 ± 0.8% 
to 6.9 ± 0.8% (mean reduction, −0.5 ± 0.8%, P < 
0.001) post-Ramadan (Fig. 1A), and proportion of pa-
tients with HbA1c < 7.5% was 48.4% at baseline that 
increased to 69.5% after Ramadan (Fig. 1B). However, 
reductions in HbA1c levels were consistent across vari-
ous age groups (< 50 years, −0.4 [0.8]; ≥ 50 to < 65 
years, −0.5 [0.8], ≥ 65 years −0.6 [1.0], P < 0.05 for 
all comparisons). Similar significant reductions in FPG 
levels (142.9 ± 54 to 121.1 ± 29.7 mg/dL; mean differ-
ence, −21.8 ± 59.4 mg/dL, P < 0.001) were observed 
(Fig. 1C) however, mean change in body weight was 
not significant (−0.3 ± 3.7 kg, P = 0.614) from baseline 
to post-Ramadan (Fig. 1D).
Adverse events
No major AEs or serious AEs were reported. Dur-
ing Ramadan, one gastroenteritis was reported in 2 
patients (n = 2, 0.8%), and one urinary tract infection 
was reported in one patient (n = 1, 0.4%), but no AEs 
were related to gliclazide XR treatment.
Discussion
This subgroup analysis of Indian patients who were 
enrolled in this international, real-world, prospective, 
observational DIA-RAMADAN study showed that most 
demographic and clinical characteristics of patients 
were similar to those of the global DIA-RAMADAN co-
hort. Indian patients observed the Ramadan fast safely 
without experiencing any HEs with negligible dropouts 
(3.7%) due to nonmedical reasons.
There is a higher risk of developing hypoglycaemia 
with SU treatment compared with other oral antidia-
betic drugs, and this led to reservations concerning 
their use in patients observing the Ramadan fast. How-
ever, it is important to note that this risk differs among 
the available SUs due to different receptor binding 
affinities and duration of action. Studies have shown 
that gliclazide was associated with a lower risk of hy-
poglycaemia in patients with T2DM who fast during 
Ramadan [8, 13–15, 18–20]. In an observational study 
comparing HEs in patients receiving vildagliptin versus 
SUs in India during Ramadan, the incidence of HEs was 
4.8% in those receiving glipizide or glibenclamide but 
not for those receiving gliclazide or glimepiride [21]. 
A meta-analysis of three randomized trials in patients 
who received a dipeptidyl peptidase 4 inhibitor or 
gliclazide during Ramadan fasting reported a similarly 
lower risk for incidence of symptomatic hypoglycaemia 
[22]. The STEADFAST study conducted in 557 patients 
fasting during Ramadan at 69 sites across 16 countries 
including the Middle East, Europe, and Asia reported 
similar rates of HEs in patients using gliclazide and 
vildagliptin [15]. A systematic review assessing efficacy 
and safety of hypoglycaemic agents in patients with 
T2DM during Ramadan fast also reported gliclazide as 
a safer option than other SUs [23]. Lower incidence of 
HEs in patients using gliclazide XR might be due to its 
selective and reversible binding to SU receptors of the 
pancreatic b-cells [24, 25]. Various guidelines on man-
Table 4. Exposure and adherence to gliclazide XR 
Exposure to gliclazide XR  Patients, n = 246
Duration of gliclazide XR treatment
Pre-Ramadan, days 63.1 ± 20.2
During Ramadan, days 29.0 ± 0.20
Post Ramadan, days 30.8 ± 10.4
Mean dose of glicliazide XR, mg
Pre-Ramadan, days 70.2 ± 24.6
During Ramadan, days 70.1 ± 24.6
Post-Ramadan, days 70.2 ± 24.7
Dose of gliclazide XR received by patients  
during Ramadan, n (%)
120 mg 40 (16.3)
90 mg 19 (7.7)
60 mg 172 (69.9)
30 mg 15 (6.1)
Gliclazide XR treatment took according 
to the prescription
240 (97.6)
Gliclazide XR skipped by patients 4 (1.6)
If yes, the number of intakes skipped 1.8 ± 0.5
If yes, reason:
AE (other than hypoglycemia) 1
Nonmedical reason 3
Adherence to treatment
Number of patients, n 240
Adherence, % 99.9 ± 0.8
Missing data, n 6
Data are presented as mean ± SD or n (%). AE: adverse event; XR: 
extended-release
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aging T2DM during Ramadan suggest adjusting the 
dose and/or timing of SU intake to reduce the risk of 
complications [3, 26]. A multicentre observational study 
reported that switching dosage time from morning to 
evening for patients on gliclazide XR monotherapy dur-
ing Ramadan could reduce the incidence of HEs [19]. 
Following the guidelines and previous studies, patients 
were advised to take gliclazide XR dose at Iftar that 
resulted in a very low incidence of HEs in the global 
DIA-RAMADAN cohort (2.2%) with no HEs reported in 
the Indian cohort.
Secondary outcomes assessed were changes in 
HbA1c, FPG, and body weight between pre-and post-
Ramadan: gliclazide XR significantly reduced HbA1c 
and FPG levels of the patients during fasting, with a 
slight but no significant change in body weight. Previ-
ously, a multicentre observational study reported a 
negligible non-significant rise in HbA1c levels (0.01%, 
P = 0.958), decrease in body weight (−0.03 kg), and 
reduction in mean FPG levels (−20 mg/dL) after treat-
ment with SU in Indian patients with T2DM who elected 
to fast during Ramadan [21]. Similarly, the STEAD-
FAST study also reported similar changes in HbA1c 
levels with vildagliptin (0.05 ± 0.04%) and gliclazide 
(−0.03 ± 0.04%) (P = 0.165), and mean reduction in 
weight (−1.1 ± 0.2 kg) with both medications (P = 
0.987) from pre- to post-Ramadan visits [15]. Overall, 
changes in HbA1c and FPG levels, and body weight in 
the Indian cohort were similar to those in the global 
DIA-RAMADAN cohort indicating that patients using 
gliclazide XR could consistently maintain glycaemic 
control and body weight without risk of hypoglycaemia 
during Ramadan fasting.
In contrast to the 40.7% of the global DIA-RAMA-
DAN population, > 70% of the Indian patients broke 
their fast during Ramadan. Of these, 2.4% of them 
Figure 1. A: HbA1c levels pre-Ramadan baseline visit (V0) and post-Ramadan visit (V1); B: Proportion of patients within strati-
fied HbA1c levels at the pre-Ramadan baseline visit (V0) and post-Ramadan visit (V1); C: Fasting plasma glucose (FPG) levels 
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broke their fast for more than three consecutive days 
due to nonmedical reasons, which was lower than 5.1% 
in the global population [17]. 
According to the IDF-DAR risk assessment at the 
pre-Ramadan visit, no Indian patients were at very 
high risk of developing hypoglycaemia, but 47 (3.9%) 
patients from the global cohort were. However, about 
43% of Indian patients were advised not to fast, and 
this proportion was also higher than that in the global 
population (24.5%) [17]. Patients from the Indian co-
hort changed their meal size (41.9%) and type (54.5%) 
and incorporated more carbohydrates (26.8%), protein 
(31.3%) or fats (43.9%) in their meals during Ramadan 
than pre-Ramadan period. Whereas, about 32% in 
the global DIA-RAMADAN study changed their meal 
type during Ramadan and 15.9% incorporated more 
carbohydrates in their meals during Ramadan [17]. 
Overall, the results of the Indian subgroup analyses 
were found to be similar to those obtained from the 
global DIA-RAMADAN population. In this study, most 
patients were on gliclazide XR alone and did not require 
dose adjustments during or post-Ramadan and showed 
high treatment adherence. This suggests that patients 
can be safely treated with gliclazide XR without dose 
adjustments during Ramadan fasting.
Limitations of the study are similar to those re-
ported in the global study mainly due to the obser-
vational nature of the study [17]. This study provided 
robust real-world evidence for managing T2DM as per 
the standard clinical practice during Ramadan in India. 
Conclusion
Overall, the effectiveness and safety of gliclazide 
XR in Indian patients was similar to the global DIA-
RAMADAN cohort. Gliclazide XR significantly reduced 
HbA1c with no incidence of hypoglycaemic events in 
Indian patients with type 2 diabetes undergoing Rama-
dan fast, suggesting the use without dose modification, 
at Iftar, to maintain optimal glycaemic control during 
Ramadan.
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